Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Rises By 5.1%

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the company’s shares are short sold. Based on an average daily trading volume, of 33,700 shares, the days-to-cover ratio is currently 19.1 days.

Greenwich LifeSciences Stock Up 1.0 %

NASDAQ:GLSI opened at $12.51 on Wednesday. Greenwich LifeSciences has a 1-year low of $10.52 and a 1-year high of $21.44. The firm’s 50-day moving average price is $12.56 and its 200-day moving average price is $13.43.

Insider Activity at Greenwich LifeSciences

In other news, CEO Snehal Patel acquired 3,200 shares of the business’s stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $11.12 per share, with a total value of $35,584.00. Following the transaction, the chief executive officer now owns 5,539,302 shares in the company, valued at $61,597,038.24. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 10,500 shares of company stock worth $128,459 over the last 90 days. 51.67% of the stock is owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in shares of Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock worth $32,000 after purchasing an additional 1,008 shares in the last quarter. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences in the fourth quarter worth $45,000. JPMorgan Chase & Co. boosted its holdings in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after acquiring an additional 4,465 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.